SUMMARY ANALYSIS

Genetic disorders are a leading contributor to morbidity and mortality in the neonatal and pediatric intensive care units in the United States. Approximately seven percent to 10 percent of the four million infants born in the U.S. each year are admitted to a neonatal Intensive Care Unit (ICU) for the diagnosis and treatment of an acute illness. About one percent of all neonatal ICU admissions have an indication of a genetic disorder, and approximately 15 percent of babies admitted to high acuity units appear to have a genetic disorder.

All organisms have a unique genetic code, or genome, comprised of nucleotide bases. If the sequence of the bases in an organism are known, its unique DNA fingerprint is known. Determining the order of bases is called sequencing. Whole genome sequencing is a laboratory procedure that determines the order of bases in the genome of an organism in one process. Rapid whole genome sequencing (rWGS) completes such sequencing quickly, and can produce a much quicker diagnosis.

CS/CS/HB 1043 requires the state Medicaid program to cover rWGS as a fee-for-service benefit for Medicaid recipients who:

- Are 20 years of age or younger;
- Have a complex or acute illness of unknown etiology that has not been caused by environmental exposure, toxic ingestion, an infection with normal response to treatment, or trauma; and
- Are receiving inpatient treatment in a hospital ICU or high-acuity pediatric care unit.

The bill would have an indeterminate, but likely significant, negative fiscal impact on state government and no fiscal impact on local government.

The bill provides an effective date of July 1, 2023.
I. SUBSTANTIVE ANALYSIS

A. EFFECT OF PROPOSED CHANGES:

Background

Genetic Disorders

Genetic disorders are a leading contributor to morbidity and mortality in neonatal and pediatric intensive care units (ICU) in the United States. There are more than 13,000 known genetic diseases and hundreds of targeted treatments and orphan drugs that have been approved or are in clinical trials.\(^1\) Approximately seven percent to 10 percent of the four million infants born in the U.S. each year are admitted to a neonatal ICU for the diagnosis and treatment of an acute illness.\(^2\) About one percent of all neonatal ICU admissions have an indication of a genetic disorder, and approximately 15 percent of babies admitted to high acuity units appear to have a genetic disorder, leading to longer hospitalizations and higher resource use.\(^3\) Disease can progress rapidly in acutely ill infants, necessitating timely diagnosis in the hope of implementing personalized interventions that can decrease morbidity and mortality.\(^4\)

Rapid Whole Genome Sequencing (rWGS)

All organisms have a unique genetic code, or genome, comprised of nucleotide bases (A, T, C, and G). If the sequence of the bases in an organism are known, its unique DNA fingerprint is known. Determining the order of bases is called sequencing. Whole genome sequencing is a laboratory procedure that determines the order of bases in the genome of an organism in one process.\(^5\) Scientists conduct whole genome sequencing by following these four main steps:\(^6\)

- **DNA shearing:** Scientists begin by using molecular scissors to cut the DNA, which is composed of millions of bases, into pieces that are small enough for the sequencing machine to read.
- **DNA bar coding:** Scientists add small pieces of DNA tags, or bar codes, to identify which piece of sheared DNA belongs to which bacteria. This is similar to how a bar code identifies a product at a grocery store.
- **DNA sequencing:** The bar-coded DNA from multiple bacteria is combined and put in a DNA sequencer. The sequencer identifies the bases that make up each bacterial sequence. The sequencer uses the bar code to keep track of which bases belong to which bacteria.
- **Data analysis:** Scientists use computer analysis tools to compare sequences from multiple bacteria and identify differences. The number of differences can tell the scientists how closely related the bacteria are, and how likely it is that they are part of the same outbreak.

rWGS can complete such sequencing quickly and produce a much quicker diagnosis in as many as 50 percent of children.\(^7\) With a turnaround as fast as 48 hours, vital time can be gained to develop and implement a plan of care for individuals, mostly children, with genetic disorders.

---


\(^3\) Id.


\(^6\) Id.
As the use of whole genome sequencing (WGS) expands, the CDC’s national surveillance systems and laboratory infrastructure must keep pace with the changing technology. With modernization, the CDC and its public health partners can continue to successfully detect, respond to, and stop infectious diseases.8

Project Baby Manatee

From August 2019 to June 2020, Nicklaus Children’s Hospital implemented a pilot program called Project Baby Manatee. Through the program, 50 patients were enrolled and sequenced using rWGS.9 The average age was 34.6 months and two-thirds were male, while 60 percent of participants were white, and 26 percent were African American.10 Two types of testing was completed – rWGS and ultra rWGS. Ultra rWGS testing was selected when delivery of the genetic diagnoses was critical for clinical management. Twenty out of 50 patients, or 40 percent, received genetic diagnoses based on WGS.11

The most common presentations of illness in which a genetic disease was diagnosed by rWGS were respiratory problems (36 percent), cardiovascular problems (36 percent), seizures (32 percent), brain disorders (32 percent), and metabolic issues (24 percent).12

Eight of the diagnosed genetic diseases in Project Baby Manatee have an incidence of less than one in one million births or are of unknown incidence. Some of the identified diseases are so rare that many treating physicians had never seen them before, increasing the probability that these disorders would generally go underdiagnosed without rWGS. The rWGS led to changes in clinical management of 38 percent of children in the pilot program. Such results empowered clinicians and parents to quickly make informed decisions that typically altered the course of the child’s hospitalization and led to the initiation of new procedures and medications, or the avoidance of unnecessary ones.13 The program resulted in estimated savings of over $3.76 million, yielding a $2.88 million return on investment.14 Based on the results of Project Baby Manatee, rWGS and related rapid precision medicine approach was cost-saving and cost-effective, but also improved health outcomes and shortened the period to diagnosis.15

Other Studies

Studies performed in clinical research settings have found genome sequencing to be effective for diagnosis and management of undiagnosed infants in ICUs and to result in improved diagnostic yield16, faster time to diagnosis, enhanced physician and parental satisfaction, improved patient outcomes, and reductions in health care costs.17 Further, rWGS facilitates end-of-life care decisions that can alleviate suffering and aid the grieving process.18 Studies have shown rWGS provides a diagnosis for 21 percent to 57 percent of children in intensive care settings.19

---

8 Supra, note 5.
10 Id., at pg. 6.
11 Id., at pg. 7.
12 Id., at pg. 8.
13 Id.
14 Id., at pg. 19. Total costs for WGS and related rapid precision medicine for 50 patients was approximately $880,000.
15 Id., at pg. 20.
19 Id.
Despite evidence that sequencing improves clinical outcomes, reduce net costs of care, and leads to high provider and parental satisfaction, routine implementation in ICUs and coverage by payors has remained elusive.\footnote{Supra, FN 5, at pg. 2.} It has been shown that rWGS, while expensive, may decrease overall cost of diagnostic evaluations of medically complex children.\footnote{Supra, FN 5, at pg. 2; \textit{R Hayeems, et al., Care and cost consequences of pediatric whole genome sequencing compared to chromosome microarray}, Eur. J. Hum. Genet., vol. 25, pgs. 1303-1312, 2017.}

Compared to traditional genetic tests, where diagnosis can be delayed or missed, rWGS has a high diagnostic yield, ranging from 40 percent to 70 percent.

Infant Mortality

Infant mortality is the death of an infant before his or her first birthday. The infant mortality rate is the number of infant deaths for every 1,000 live births. In 2020, the infant mortality rate in the United States was 5.4 deaths per 1,000 live births.\footnote{U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, \textit{Publication and Information Products–Data Briefs, Mortality in the United States, 2020}, available at \url{https://www.cdc.gov/nchs/products/databriefs/db427.htm#section_5} (last visited on April 5, 2023).}

The following map shows infant mortality by state for 2020, the most recent year with available data. Florida’s infant mortality rate is 4.96 to less than 6.62 per 1,000 live births.\footnote{U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, \textit{Reproductive Health, Maternal and Infant Health, Infant Mortality Rates by State, 2020}, available at \url{https://www.cdc.gov/reproductivehealth/maternalinfanthealth/infantmortality.htm} (last visited on April 5, 2023).}

![Death Rates Map](image_url)
shows the infant mortality rate for the 10 leading causes of infant death in 2020 in the United States, with 2019 rates included for comparison.\textsuperscript{24}

The chart below shows the leading cause of death of infants in Florida for 2021, with 2020 rates included for comparison.\textsuperscript{25}

Florida Medicaid

Medicaid is the health care safety net for low-income Floridians. Medicaid is a partnership of the federal and state governments established to provide coverage for health services for eligible persons. The

\textsuperscript{24} Supra, FN 22, figure 5.

program is administered by the Agency for Health Care Administration (AHCA) and financed by federal and state funds.

The structure of each state’s Medicaid program varies, but what states must pay for is largely determined by the federal government, as a condition of receiving federal funds. The federal government sets the minimum mandatory populations to be included in every program, and the minimum mandatory benefits to be covered. These mandatory benefits include physician services, hospital services, home health services, and family planning. States can add benefits, with federal approval. Florida has added many optional benefits.

The Florida Medicaid program covers approximately 5.7 million low-income individuals in Florida. Medicaid is the largest single program in the state, representing more than 44 percent of the total Fiscal Year (FY) 2022-2023 state budget. Florida’s program is the 4th largest in the nation by enrollment and, for FY 2020-2021, the program is the 4th largest in terms of expenditures.

Florida delivers medical assistance to most Medicaid recipients - approximately 78% - using a comprehensive managed care model. A minority of Medicaid recipients-mostly those enrolled in limited benefit programs-participate in the traditional fee-for-service model.

Payment for Genomic Testing

Florida’s Medicaid program pays for the following standard, non-rapid genomic sequencing procedures:

- Fetal chromosomal aneuploidy genomic sequence analysis panel.
- Fetal chromosomal microdeletion genomic sequence analysis.
- Genomic sequencing procedures and other molecular multianalyte assays.
- Genetic testing for severe inherited conditions.

Several states are currently implementing coverage policies for rWGS, including California, Minnesota, Louisiana, Maryland, and Oregon.

Over the past decade, rWGS has developed into an effective diagnostic test for almost all heritable diseases and is gaining acceptance as a first-tier test for critically ill newborns with suspected genetic diseases. While there has been an increase in payor coverage for rWGS, it varies and is not universal.

---

27 S. 409.905, F.S.
28 S. 409.906, F.S.
32 S. 409.964, F.S.
33 Agency for Health Care Administration, 2023 Agency Legislative Administration—HB 1043, pg. 2, March 7, 2023, on file with the House Healthcare Regulation Subcommittee.
34 Medi-Cal Update, Inpatient Services, Bulletin 573, June 2022.
36 Louisiana SB 154, Provides for Health Insurance Coverage of Genetic Testing for Critically Ill Infants with No Diagnosis, January 1, 2023.
39 Supra, FN 1.
Effect of Proposed Changes

CS/CS/HB 1043 creates s. 409.9063, F.S., which requires AHCA to seek approval from the Centers for Medicare and Medicaid Services to cover rWGS as a benefit for Medicaid recipients who:

- Are 20 years of age or younger;
- Have a complex or acute illness of unknown etiology that has not been caused by environmental exposure, toxic ingestion, an infection with normal response to treatment, or trauma; and
- Are receiving inpatient treatment in a hospital ICU or high-acuity pediatric care unit.

The bill provides an effective date of July 1, 2023.

B. SECTION DIRECTORY:

Section 1: Creates s. 409.9063, F.S., relating to rapid whole genome sequencing services for Medicaid recipients.

Section 2: Provides an effective date of July 1, 2023.

II. FISCAL ANALYSIS & ECONOMIC IMPACT STATEMENT

A. FISCAL IMPACT ON STATE GOVERNMENT:

1. Revenues:

   None.

2. Expenditures:

   The bill would have an indeterminate, but likely significant, negative fiscal impact on state expenditures related to the Medicaid program, to the extent that qualified Medicaid recipients consent to rWGS services.

   In 2021, 14,476 newborn babies covered by Medicaid were admitted to a NICU facility. If 5 percent (724) of those newborns were tested and assuming testing was reimbursed as a fee-for-service benefit, the total potential expense would be $3,292,791, with potential impact to General Revenue Fund totaling $1,334,239. The chart below details potential expenses as the percentage of newborns tested increases. This projection is based on the number of newborn children in a NICU in 2021, and a reimbursement rate of 60% of the Medicare reimbursement rate for rWGS ($7,582.20 x 60% = $4,549.31). The fiscal impact may be significantly higher than this projection, because the bill provides for rWGS services to all qualified Medicaid recipients aged 20 years or younger, to include newborns.

<table>
<thead>
<tr>
<th>Participation Rate</th>
<th>Potential Participants</th>
<th>Total Expense</th>
<th>GR Impact</th>
</tr>
</thead>
<tbody>
<tr>
<td>5%</td>
<td>724</td>
<td>$3,292,791</td>
<td>$1,334,239</td>
</tr>
<tr>
<td>10%</td>
<td>1,448</td>
<td>$6,585,581</td>
<td>$2,668,477</td>
</tr>
<tr>
<td>15%</td>
<td>2,171</td>
<td>$9,878,372</td>
<td>$4,002,716</td>
</tr>
<tr>
<td>25%</td>
<td>3,619</td>
<td>$16,463,953</td>
<td>$6,671,194</td>
</tr>
<tr>
<td>50%</td>
<td>7,238</td>
<td>$32,927,906</td>
<td>$13,342,387</td>
</tr>
<tr>
<td>75%</td>
<td>10,857</td>
<td>$49,391,859</td>
<td>$20,013,581</td>
</tr>
<tr>
<td>100%</td>
<td>14,476</td>
<td>$65,855,812</td>
<td>$26,684,775</td>
</tr>
</tbody>
</table>

AHCA will need to determine reimbursement rates for Medicaid coverage of rWGS.

---

40 Agency for Health Care Administration, 2023 Agency Legislative Bill Analysis–HB 1043, March 7, 2023, pg. 5, on file with the House Healthcare Regulation Subcommittee.
B. FISCAL IMPACT ON LOCAL GOVERNMENTS:
   1. Revenues:
      None.
   2. Expenditures:
      None.

C. DIRECT ECONOMIC IMPACT ON PRIVATE SECTOR:
   None.

D. FISCAL COMMENTS:
   Neither the bill nor the House Fiscal Year 2023-2024 budget appropriate funds to cover the cost of rWGS under the bill. Future expenditures related to rWGS would be considered by the Social Services Estimating Conference in the Medicaid Expenditures forecast.

III. COMMENTS

A. CONSTITUTIONAL ISSUES:
   1. Applicability of Municipality/County Mandates Provision:
      Not applicable. The bill does not impact municipal or county government.
   2. Other:
      None.

B. RULE-MAKING AUTHORITY:
   The bill and current law provide AHCA with sufficient rulemaking authority to implement the bill provisions.

C. DRAFTING ISSUES OR OTHER COMMENTS:
   None.

IV. AMENDMENTS/COMMITTEE SUBSTITUTE CHANGES

On April 3, 2023, the Healthcare Regulation Subcommittee adopted two amendments and reported the bill favorably as a committee substitute. The amendments:

- Removed the whereas clauses from the bill.
- Changed the age of eligibility for rWGS under Medicaid to 20 years of age and younger.

On April 17, 2023, the Health and Human Services Committee adopted one amendment and reported the bill favorably as a committee substitute. The amendment removed bill provisions dictating how and when genetic data received from rWGS may be used and establishing terms for scientific participation.

The bill was reported favorably as amended. The analysis is drafted to the committee substitute as passed by the Health and Human Services Committee.